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ABSTRACT
Cancer stem cells (CSCs), which play important roles in tumor initiation and 
progression, are resistant to many types of therapies. However, the regulatory 
mechanisms underlying CSC-specific properties, including self-renewal, are poorly 
understood. Here, we found that LATS1/2, the core Hippo pathway-kinases, were 
highly expressed in the oral squamous cell carcinoma line SAS, which exhibits high 
capacity of CSCs, and that depletion of these kinases prevented SAS cells from 
forming spheres under serum-free conditions. Detailed examination of the expression 
and activation of LATS kinases and related proteins over a time course of sphere 
formation revealed that LATS1/2 were more highly expressed and markedly activated 
before initiation of self-renewal. Moreover, TAZ, SNAIL, CHK1/2, and Aurora-A were 
expressed in hierarchical, oscillating patterns during sphere formation, suggesting 
that the process consists of four sequential steps. Our results indicate that LATS1/2 
trigger self-renewal of CSCs by regulating the Hippo pathway, the EMT, and cell 
division.
INTRODUCTION
Cancer stem cells (CSCs), also called tumor-
initiating cells (TICs), drive tumorigenesis and tumor 
heterogeneity through their abilities to self-renew and 
generate tumorigenic progeny. These cells are also 
resistant to a wide range of therapeutic agents, including 
chemotherapy and radiotherapy, and thus promote 
cancer progression and tumor recurrence [1, 2, 3, 4, 
5]. Importantly, CSC-specific properties such as self-
renewal and chemoresistance are associated with the 
epithelial–mesenchymal transition (EMT), a cellular 
program that promotes invasion and metastasis during 
cancer development [6, 7, 8, 9, 10, 11]. For instance, 
EMT induced by ectopic expression of EMT-regulated 
transcription factors (EMT-TFs) such as SNAIL (SNAI1) 
and TWIST endows mammary epithelial cells with CSC 
properties [6]. In addition, a study using a knock-in 
reporter mouse line for Snail (Snail-YFP) demonstrated 
that breast TICs expressing Snail undergo the EMT [12]. 
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These findings imply that, through activation of EMT-TFs, 
especially SNAIL, the EMT is a leading cause of cancer 
stemness in a variety of tumors [13, 14, 15]. Moreover, 
diverse signaling pathways, including Hippo, WNT, 
SHH (sonic hedgehog), NOTCH, and the DNA damage 
response (DDR), are involved in CSC properties and the 
EMT [16, 17, 18, 19, 20, 21]. Although these studies have 
advanced our understanding, the molecular mechanisms 
underlying CSC-specific properties, especially their 
capacity to initiate and maintain self-renewal, have yet to 
be fully elucidated.
LATS1 and LATS2 (LATS1/2), the core kinases 
of the Hippo pathway, regulate tissue homeostasis 
and tumorigenesis by preventing cell proliferation or 
promoting cell death through a phosphorylation signaling 
cascade [22, 23, 24]. In this cascade, LATS1/2 are 
activated by two upstream kinases, MST1 and MST2, in 
response to divergent stimuli such as cell–cell contact, 
serum starvation, cell polarity, and mechanical features, 
and then directly phosphorylate two transcriptional co-
factors, YAP (on S127) and TAZ (on S89). Phosphorylation 
represses the nuclear activities of YAP/TAZ by promoting 
their association with 14-3-3 protein, resulting in their 
cytoplasmic retention. LATS1/2 also promote the 
degradation of YAP/TAZ proteins by phosphorylation-
mediated ubiquitination via an interaction with the 
β-TrCP E3 ubiquitin-ligase complex. Consistent with 
this, in many human malignant tumors, such as liver, 
colon, breast, and oral cancers, YAP/TAZ are activated, 
whereas LATS1/2 are inactivated [25, 26, 27, 28]. Notably, 
LATS1/2 play pivotal roles in the control of cell fate, not 
only by inhibiting YAP/TAZ in a manner dependent on 
the canonical Hippo pathway, but also by regulating a 
tumor-suppressive transcriptional factor p53, Polycomb 
repressive complex 2 (PRC2), SNAIL, and cell cycle 
checkpoint regulators including mitotic kinases of the 
Aurora family, the cofilin regulator LIM-kinase 1, and 
the centrosomal protein phosphatase CDC25B [29, 30]. 
Thus, LATS1/2 also regulate chromosomal instability, 
DDR, EMT, metastasis, cell division, and cell stemness. 
Recent studies showed that YAP/TAZ are required for 
the maintenance and expansion of CSCs in various solid 
tumors [28, 31]. For instance, TAZ confers self-renewal 
capacity, a CSC property, on breast, brain, and oral cancer 
cells, probably by inducing the EMT [21, 32, 33, 34]. 
Similarly, YAP confers some CSC properties, such as 
sphere formation and chemoresistance, on hepatocellular 
carcinoma, esophageal cancer, osteosarcoma, and basal-
like breast cancer cells by coordinating the expression of 
interleukin 6 (IL-6) and stemness marker proteins such as 
SOX2, SOX9, and CD90 [35, 36, 37, 38]. Nevertheless, 
the biological roles of LATS1/2, as well as the mechanisms 
by which they enable cancer cells to acquire and maintain 
CSC properties, are incompletely understood.
The most frequently observed form of head-
and-neck cancer in Southeast Asia is oral squamous 
cell carcinoma (OSCC), which is the most commonly 
emerging cancer worldwide. Survival rates of patients 
with advanced OSCC have not increased significantly 
in recent years [39]. This is partly due to the large 
proportion of patients with advanced stages of disease, 
which may not respond to any available therapies [40, 
41]. To develop effective therapeutic strategies against 
OSCC, it is crucial to understand the detailed molecular 
mechanisms underlying CSC properties in this disease. 
Such knowledge would facilitate the identification of 
useful CSC markers [42]. Successful isolation of CSCs 
from OSCCs (e.g., the SAS cell line) using non-adhesive 
culture systems represents a promising advance in this 
research field. SAS cells exhibit the full spectrum of CSC-
specific properties: stemness, self-renewal, chemo- and 
radioresistance in vitro, and tumor initiation capacity in 
vivo [43].
In this study, using SAS cells as a model of CSCs 
in OSCC, we showed that LATS1/2 are essential for self-
renewal of CSCs, and in particular for the initiation of 
sphere formation. Notably, we found that the expression 
patterns of LATS1/2 oscillated over the course of sphere 
formation of CSCs under serum-free conditions, and that 
these kinases were activated just before self-renewal (cell 
division). This temporal pattern was associated with the 
hierarchical oscillating expression of TAZ (but not YAP), 
SNAIL, CHK1/2, and Aurora-A. Loss of any of the latter 
proteins prevented SAS cells from forming spheres. These 
results imply that the process of sphere formation in CSCs 
consists of four sequential steps. Based on these findings, 
we propose the existence of a special stage (the “pre-SR 
stage”) that serves as a preliminary step for the initiation 
of self-renewal.
RESULTS
LATS1 and LATS2 are overexpressed in SAS cells
SAS is an OSCC cell line that exhibits 
prominent CSC properties, including sphere formation, 
radioresistance, multidrug resistance, and tumor 
formation [43, 44, 45]. Spheres of SAS cells also express 
high levels of representative stem cell markers such as 
CD133 and ALDH1 and pluripotent transcription factors 
such as SOX2, OCT4, and NANOG. In contrast to SAS 
cells, OSCC cell lines such as HSC3 and HSC4 do not 
form spheres and are highly chemosensitive [44]. Thus, 
SAS cells are useful tools for analyzing the molecular 
mechanisms underlying CSC properties. Because SAS 
cells readily form spheres with CSC properties in non-
adhesive culture systems [43, 45], they are an ideal model 
for investigating the self-renewal of CSCs.
To identify the signaling pathway driving cancer 
stemness (a cancer-initiating property) in OSCC, we 
examined self-renewal potential in SAS cells by assessing 
their capacity to form and propagate spheres in vitro 
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(Figure 1A). When SAS and HSC3 cells were incubated on 
ultra–low attachment surface plates under sphere-forming 
conditions in the absence of serum, SAS cells formed 
spheres at high frequency, whereas HSC3 cells barely 
aggregated (Figure 1B). Consistent with previous results 
[44, 45], these observations indicate that SAS cells have 
significantly greater self-renewal potential than HSC3 cells.
Next, we asked whether the difference in CSC-
related properties, including the ability to form spheres, 
between SAS, HSC3, and HSC4 cells is due to differential 
expression of the canonical Hippo pathway regulators 
such as LATS1/2 and YAP/TAZ. Under conventional 
adherent conditions in the presence of serum, protein 
levels of LATS1/2 were markedly higher in SAS cells 
than in HSC3 and HSC4 cells (Figure 1C). Consistent with 
a theory of the canonical Hippo pathway that LATS1/2 
inhibit YAP and TAZ, YAP and TAZ were absent or 
present at very low levels in SAS cells (Figure 1C, lane 3). 
However, LATS1/2-mediated inhibitory phosphorylation 
of YAP-S127 (pS127) did not differ significantly among 
the three cell lines. Unexpectedly, HSC4 cells expressed 
higher levels of YAP and TAZ compared with HSC3 cells, 
independent of the levels of LATS1/2 (Figure 1C, lane 
2). These results suggest that, in SAS cells, LATS1/2 are 
potentially overexpressed and probably activated, and thus 
inhibit YAP and TAZ without promoting their cytoplasmic 
retention. Indeed, western blot analysis of cell extracts 
fractionated into cytoplasm, cell membrane, nucleus, and 
cytoskeleton revealed that, in SAS cells, the level of YAP-
pS127 was not elevated in the cytoplasm, even though 
LATS1/2 were highly expressed, and that the levels of 
YAP and TAZ were lower than in HSC3 and HSC4 (Figure 
1D, lane 9). A portion of YAP and TAZ localized in the 
nuclear fraction in HSC3 and HSC4 cells, but not in SAS 
cells (Figure 1D, lanes 3, 7, and 11; Supplementary Figure 
1B, lanes 3 and 7). Consistent with previous reports, 
LATS2 was present in all four fractions (Figure 1D, lanes 
9–12). In addition, phosphorylation of 14-3-3 protein on 
S59, a target of LATS2 kinase [46], was elevated in the 
cytoplasm and cell membrane fractions of SAS cells, 
suggesting that LATS2 is activated in these cells.
When the Hippo pathway is activated, YAP and 
TAZ are destabilized by LATS1/2- and CK2-mediated 
phosphorylation, and subsequently degraded via the 
ubiquitin–proteasome system [47, 48]. To investigate the 
mechanism responsible for reduced expression of YAP 
in SAS cells, we treated cells with MG132, a proteasome 
inhibitor, and then fractionated extracts as in Figure 1D 
(Supplementary Figure 1A). MG132 treatment restored the 
YAP protein level (Supplementary Figure 1B, lane 9). We 
also found that Scribble, an upstream regulator of the Hippo 
pathway to determine the cell polarity, was overexpressed 
and localized to the cell membrane in SAS cells (Figure 
1C, sixth panel from top; 1d, seventh panel from top). 
In epithelial breast cancer cells, Scribble facilitates 
interactions between the core Hippo kinases (MST1/2 
and LATS1/2) and TAZ, which acts as a scaffold protein, 
thereby destabilizing and preventing activation of TAZ 
[21]. Accordingly, the downregulation and delocalization of 
Scribble may be sufficient for stabilization of TAZ in HSC3 
and HSC4 cells. By contrast, in SAS cells, LATS1/2 might 
be activated, thereby downregulating TAZ by anchoring 
Scribble to the cell membrane. Indeed, in SAS cells 
LATS1/2 were activated by MST2 by phosphorylating their 
respective target sites, T1079 and T1041, (Supplementary 
Figure 1C, lane 3). Taken together with the phosphorylation 
of YAP-pS127 in SAS cells, these results suggest that YAP, 
and probably also TAZ, is inhibited in SAS cells via protein 
degradation, rather than via cytoplasmic retention mediated 
by binding to 14-3-3 protein.
LATS1/2 are required for sphere formation in 
CSCs
To determine whether LATS1/2 are important 
factors for sphere formation in CSCs, we knocked down 
endogenous LATS1 or LATS2 using siRNA in SAS 
cells, and then grew the cells for one more day under 
conventional adherent culture conditions (termed “SAS-a” 
for “attached SAS”; Figure 2A, lanes 1 and 2) or in sphere-
forming conditions without serum (termed “SAS-s” for 
“spheres”; Figure 2A, lanes 3 and 4). The level of LATS1 
was elevated, whereas the level of Scribble was reduced, 
in SAS-s in comparison with SAS-a (Figure 2A, lanes 
3 and 4). Expression of TAZ in SAS cells was very low 
(Figure 1C), and could not be detected unless the western 
blot exposure time was lengthened (Figure 2A, second 
and third panels from top); in any event, TAZ levels 
did not differ between the two conditions. Importantly, 
depletion of LATS1 inhibited sphere formation by 
SAS cells, whereas negative control cells (siGL2/SAS) 
formed spheres normally (Figure 2B). As with LATS1, 
knockdown of LATS2 also inhibited sphere formation by 
SAS cells (Figure 2C, 2D). Notably, depletion of LATS1 
or LATS2 did not promote drastic accumulation of TAZ in 
SAS-a or SAS-s, although the active (non-phosphorylated) 
form of TAZ was slightly more abundant in LATS-
knockdown cells (arrows in Figure 2A, 2C). To confirm 
the importance of LATS kinases in initiation of sphere 
formation, we measured the frequency of primary spheres 
> 20 μm in diameter in LATS1/2-depleted (siLATS1/SAS 
and siLATS2/SAS) and control SAS cells (siGL2/SAS). 
As expected, siLATS1/SAS and siLATS2/SAS suppressed 
sphere formation (frequency of spheres, ~5–10%), 
whereas siGL2/SAS generated a larger number of spheres 
after day 1 (20–40%) (Figure 2E, 2F). Double knockdown 
of LATS1/2 also suppressed the sphere formation (~15%), 
although the synergistic effect of LATS1 and LATS2 
kinases was not observed in this assay (Supplementary 
Figure 1D, 1E). Furthermore, we confirmed that double 
knockdown of LATS1/2 suppressed sphere formation by 
another OSCC cell line, SCC-4 (Supplementary Figure 1F, 
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Figure 1: LATS1/2 are overexpressed and YAP/TAZ are downregulated in SAS cells in the adherent state. (A) Phase 
contrast images of spheres from HSC3 (top) and SAS (bottom) cell lines seeded at 400 cells/cm2 in 100 mm low-adhesion sphere culture 
dishes and grown for 6 days. Scale bars represent 100 μm. (B) Quantification of sphere-forming ability of HSC3 (orange bars) and SAS 
(blue bars) cells. Bar graphs show the percentages of spheres (> 20 μm diameter) among total cells (HSC3, > 200 cells; SAS, > 170 
cells). (C) Western blot analysis of the indicated Hippo pathway regulators in HSC3, HSC4, and SAS cells growing under adherent 
culture conditions. GAPDH was used as a loading control. The levels of the indicated proteins were normalized against the level 
of GAPDH. Expression patterns of other proteins, including α-tubulin, were shown in Supplementary Figure 1C. (D) HSC3, HSC4, 
and SAS cells were cultured under adherent conditions and fractionated into cytoplasm, cell membrane, nucleus, and cytoskeleton, 
followed by western blotting with the indicated antibodies. YAP and YAP (GS) are monoclonal (clone H-9) and polyclonal antibodies, 
respectively. 14-3-3 and MAPK are cytoplasmic markers; Lamin A/C is a nuclear marker; and E-cadherin is a cell membrane marker. 
Another cytoskeleton marker, vimentin, was detected only in the cytoskeleton fraction of HSC3, suggesting that HSC4 and SAS cells 
might retain epithelial properties.
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1G, 1H); however, unlike SAS cells, TAZ was detectably 
expressed in adherent SCC-4 cells (Supplementary Figure 
1F, third panel from top). These results suggest that the 
LATS1/2 are required for self-renewal of CSCs, especially 
in the early initiation phase of sphere formation.
Downregulation of TAZ is not essential for 
initiation of sphere formation in OSCCs
In human oral cancer, TAZ promotes cancer 
stem cell maintenance [34]. We found that TAZ was 
Figure 2: LATS1 and LATS2 are required for the sphere formation by SAS cells. (A) SAS cells were transfected with siRNAs 
against LATS1 (siLATS1) or firefly luciferase as a negative control (siGL2), and cultured for 3 days under adherent culture conditions 
(SAS-a) or non-adherent sphere culture conditions (SAS-s). Cell lysates were subjected to western blotting with the indicated antibodies. 
A long-exposure western blot of TAZ (Long exp.) is shown in the third panel from the top. Asterisks and arrow show phosphorylated and 
non-phosphorylated (active) forms of TAZ, respectively. α-tubulin was used as a loading control. The levels of the indicated proteins were 
normalized against the level of α-tubulin. (B) Representative phase contrast images of LATS1-depleted (siLATS1/SAS) and control SAS 
(siGL2/SAS) cells, grown under sphere formation conditions, on days 1 and 3. White arrows indicate spheres. Scale bars represent 100 
μm. (C) SAS cells were transfected with siRNAs against LATS2 (siLATS2) and cultured as in A. Cell lysates were subjected to western 
blotting with the indicated antibodies. Arrowhead indicates LATS2. Asterisks and arrow show phosphorylated and non-phosphorylated 
(active) forms of TAZ, respectively. α-tubulin was used as a loading control. The levels of LATS2 protein were normalized against the level 
of α-tubulin. (D) Representative phase contrast images of LATS2-depleted (siLATS2/SAS) and siGL2/SAS cells. Images were obtained as 
in B. White arrows indicate spheres. Scale bars represent 100 μm. (E) Frequency of sphere formation in siLATS1/SAS (purple bars) and 
siGL2/SAS (blue bars) cells, grown under sphere formation conditions, on days 1 and 3. More than 100 cells were counted on day 1, and 
more than 50 cells were counted on day 3. (F) Frequency of sphere formation in siLATS2/SAS (orange bars) and siGL2/SAS (blue bars) 
cells, grown under sphere formation conditions, on days 1, 3, and 5. More than 200 cells were counted.
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downregulated in CSC-like OSCC cells, such as SAS, 
whereas its expression was maintained at a higher level 
in OSCC cells that do not form spheres, such as HSC3 
and HSC4 (Figure 1B, 1C). To determine whether sphere 
formation by OSCC cells requires downregulation of 
TAZ, we transfected HSC3 cells with siRNA against 
TAZ (Figure 3A). Knockdown of endogenous TAZ 
weakly promoted the initiation of sphere formation 
until day 3 (< 10%), but this frequency of spheres was 
not maintained thereafter (Figure 3B, 3E). These results 
suggest that downregulation of TAZ does not confer high 
sphere formation capacity on HSC3 cells. Consistent with 
this, HSC4 cells, which also have low sphere formation 
capacity, also expressed higher levels of TAZ (Figure 
1C, lane 2). Unsurprisingly, knockdown of TAZ did not 
increase sphere formation capacity in SAS cells (Figure 
3C, 3D, 3F). Rather, knockdown of TAZ tended to 
decrease sphere formation capacity (red bars in Figure 
3F). In contrast to the intracellular behavior of TAZ, a 
large fraction of YAP localized in the cytoplasm, but not 
the nucleus, in HSC3 cells (Figure 1D). Because YAP 
was also downregulated in SAS cells, we asked whether 
overexpression of YAP would prevent sphere formation 
in SAS cells (Supplementary Figure 2A). Overexpression 
of YAP did not prevent or promote sphere formation 
by SAS cells (Supplementary Figure 2B). Based on the 
consensus that cytoplasmic sequestration of YAP blocks its 
oncogenic activity, these results suggest that YAP makes a 
less important contribution than TAZ to growth and sphere 
formation of OSCC cells, including HSC3 and SAS.
LATS1/2 are activated in CSCs at the 
preliminary stage of self-renewal
To examine the roles of LATS1/2 in the initiation 
of sphere formation, we analyzed the temporal expression 
patterns and activation states of LATS1/2 during sphere 
formation by SAS cells. The cells were transferred onto 
an ultra–low attachment surface plate in sphere culture 
medium without serum, and then incubated for 1 h to 10 
days (Figure 4A). Sphere morphology was monitored 
by observing time-dependent changes in spheres formed 
by single cells. Each cell divided into two daughter 
cells after approximately 1 day (24 h) of culture under 
sphere-forming conditions, and subsequently grew, 
generating a small floating sphere at 3–5 days and a large 
typical sphere with round smooth contours at 7–10 days 
(Figure 4B). Western blot analyses revealed that levels of 
LATS1/2 were markedly elevated at 6–24 and 12–24 h, 
respectively, but decreased or disappeared at 48 and 72 h 
(Figure 4C, top and second panels; Supplementary Table 
1). Moreover, LATS1/2 were strongly phosphorylated and 
activated by MST kinase(s), with a peak at 12 h. Notably, 
phosphorylation of LATS2 on T1041 was temporarily 
reduced to undetectable levels after transfer of cells into 
sphere medium, and was maintained at low levels for 6 
h, but then increased dramatically at 12 h (Figure 4C, 
fourth panel from top). Unlike LATS2, phosphorylation 
of LATS1 on T1079 was maintained at low levels, similar 
to those in adherent SAS cells, until 6 h (Figure 4C, third 
panel from top). Consistent with these results, MST1/2 
(pT183/pT180) were phosphorylated and activated with 
a peak at 3–6 h, whereas TAZ levels (phosphorylated and 
unphosphorylated forms) were increased and stabilized 
in response to inactivation of LATS2 at 1–6 h (Figure 
4C, sixth and seventh panels from top). However, no 
increase in the YAP level was observed during sphere 
formation (Figure 4C, bottom panel). Based on these 
results, we categorize the process of sphere formation 
into four stages, as follows: (1) early stage (1–6 h); (2) 
pre–self-renewal (pre-SR) stage, a preliminary phase of 
self-renewal (12 h); (3) initiation of self-renewal (in-SR) 
stage, in which self-renewal (cell division) is executed (24 
h); and (4) sphere formation stage, during which mature 
spheres grow (from about 48 h onward after initiation 
of the culture under sphere-forming conditions) (Figure 
4A). In this context, it is likely that the completion of 
sphere formation requires the following steps: activation 
of TAZ, mediated by downregulation of LATS2, during 
the early stage; transient re-activation of LATS1/2 during 
the pre-SR and in-SR stages, which is accompanied by 
degradation of TAZ; and finally inactivation of LATS1/2 
during the sphere formation stage. Our results also suggest 
that constitutive activation or inhibition of LATS or TAZ 
throughout sphere formation fails to confer self-renewal 
capacity on CSCs (Figures 2, 3).
Generation of mammalian cells with CSC 
properties involves the EMT and its regulators, e.g., 
SNAIL and TWIST [6]. Moreover, the EMT promotes 
self-renewal through the Hippo pathway; specifically, 
downregulation of Scribble and the subsequent 
activation of TAZ promote breast cancer stemness [21]. 
Because SNAIL activity is correlated with LATS2-
mediated T203 phosphorylation during the EMT [25], 
we asked whether SNAIL is phosphorylated by LATS2 
during sphere formation by SAS cells. As expected, 
T203 of SNAIL became intensely phosphorylated 
after incubation under sphere-forming conditions. 
After 6–24 h, when LATS1/2 were upregulated, the 
protein appeared as multiple bands, likely due to other 
phosphorylation events by unknown kinases (Figure 4D, 
top panel, lanes 4–6). Consistent with this, expression of 
N-cadherin, a mesenchymal marker and transcriptional 
target of SNAIL, was induced at 24–72 h immediately 
after the activation of LATS and SNAIL, suggesting 
that self-renewal of OSCCs is also associated with the 
EMT (Figure 4D, third panel from top). Interestingly, 
phosphorylation of T203 on SNAIL diminished at 48–72 
h, similarly to LATS (Figure 4D, top panel, lanes 7 and 
8), but accumulation of TAZ was no longer restored by 
a reduction in LATS activity (Figure 4C, seventh panel 
from top, lanes 7 and 8).
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Cell cycle and DNA damage checkpoint regulators 
are also thought to play important roles in promoting 
CSC-like properties, including sphere formation, 
radioresistance, EMT, and tumorigenesis [20, 49]. Indeed, 
the DNA damage checkpoint kinases CHK1 and CHK2 
are highly expressed and activated in CSCs of gliomas, 
in which they promote efficient DNA repair, thereby 
inducing radioresistance [50]. Moreover, the mitotic 
kinase Aurora-A (AURKA) is also highly expressed in the 
nucleus of breast CSCs, and promotes sphere formation, 
radioresistance, invasion, and metastasis in breast and 
laryngeal cancer cells [51, 52, 53]. Therefore, these 
Figure 3: Downregulation of TAZ is insufficient to promote sphere formation in HSC3 cells. (A) HSC3 cells were transfected 
with TAZ siRNA (siTAZ) and siGL2, and cultured for 3 days under adherent culture conditions (HSC3-a). Cell lysates were subjected to 
western blotting with the indicated antibodies. Arrow indicates TAZ. α-tubulin was used as a loading control. (B) Representative phase 
contrast images of TAZ-depleted (siTAZ/HSC3) and control HSC3 (siGL2/HSC3) cells, grown under sphere formation conditions, on days 1 
and 3. White arrows indicate spheres. Scale bars represent 100 μm. (C) SAS cells were transfected with siTAZ and siGL2, and cultured as in 
A. Cell lysates were subjected to western blotting with the indicated antibodies. A long-exposure image of TAZ protein (Long exp.) is shown 
in the second panel; TAZ was expressed at a low level in SAS cells (see also Figure 1C). Asterisks and arrow show phosphorylated and 
non-phosphorylated (active) forms of TAZ, respectively. α-tubulin was used as a loading control. (D) Representative phase contrast images 
of TAZ-depleted (siTAZ/SAS) and siGL2/SAS cells. Images were obtained as in B. White arrows indicate spheres. Scale bars represent 100 
μm. (E) Frequency of sphere formation in siTAZ/HSC3 (reddish orange bars) and siGL2/HSC3 (dark blue bars) cells, grown under sphere 
formation conditions, on days 1, 3, and 5. Numbers (n) above bar graphs represent total cell count, including spheres. (F) Frequency of 
sphere formation in siTAZ/SAS (orange and red bars) and siGL2/SAS (light blue and dark blue bars) cells, grown under sphere formation 
conditions, on days 1 and 3. More than 200 cells were counted on day 1, and more than 180 cells were counted on day 3. Data from three 
independent experiments (Exp. #1–#3) were shown by each bar graph. Numbers above bar graphs represent percentage of spheres.
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proteins represent potential cancer stemness markers. 
CHK1/2 and Aurora-A directly phosphorylate and activate 
LATS2 via a Hippo–YAP/TAZ axis–independent pathway 
[46, 54, 55]. Therefore, we examined the expression 
patterns of CHK1/2 and Aurora-A during sphere formation 
of SAS cells. The expression levels of these kinases were 
Figure 4: Expression and activation of LATS1 and LATS2 are elevated at the pre–self-renewal stage of sphere 
formation. (A) Schematic depicting the time course analysis of sphere formation, which was classified into four stages: early stage (1–6 
h after start of incubation in sphere medium), pre–self-renewal stage (pre-SR; at 12 h), self-renewal initiation stage (first division; at 24 h), 
and sphere formation stage (cell aggregation; from 48 h onward). (B) Representative bright field images of sphere-forming SAS cells during 
the time course analysis. SAS cells were plated on ultra–low attachment surface plates and cultured in sphere medium for the indicated 
times, as in A. The early, pre-SR, self-renewal initiation, and sphere formation stages are highlighted by labeling with light blue, purple, 
pink, and orange, respectively. Arrows indicate two daughter cells at first division (24 h after incubation in the sphere medium). Scale 
bars represent 100 μm. (C, D) Western blot analysis of the lysates from sphere-forming SAS cells, collected at the time points indicated 
in A. Expression levels of the canonical Hippo pathway–related proteins (C) and the LATS1/2 axis–related proteins and phosphorylations 
(D) were examined by probing with the indicated antibodies. Arrow, arrowhead, and asterisk indicate MST2-pT180, LATS2-pS835, and 
non-specific bands, respectively. α-tubulin was used as a loading control. A indicates SAS-a (attached SAS cells under adherent culture 
conditions). The ratio of band intensity was shown in Supplementary Table 1.
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significantly elevated and maintained during the pre-SR 
and in-SR stages (12–24 h), and then modestly decreased 
during the sphere formation stage (Figure 4D, fourth to 
sixth panels from top, lanes 5–8), suggesting that these 
kinases also play important roles in self-renewal of 
CSCs in OSCC and other cancer cell lines. Moreover, 
the expression levels of CHK1 and Aurora-A and the 
phosphorylation level of S408 on LATS2 by CHK1 were 
higher in adherent SAS cells than in non-CSCs such as 
HSC3 and HSC4 (Supplementary Figure 1C, fourth to 
seventh panels). Interestingly, the phosphorylation level 
of S835 on LATS2 by CHK1-dependent LATS2 trans-
autophosphorylation, which is important for LATS2 
activation [55], was increased during sphere formation 
and peaked at 12–24 h, whereas S408 phosphorylation 
level was maintained at comparatively low levels during 
the early stage and gradually decreased after the early 
stage (Figure 4D, ninth and tenth panels from top). 
The dephosphorylation of S408 after the early stage 
might also play an important role in sphere formation. 
Notably, c-MYC, a transcription factor that functions as 
an oncoprotein, is highly expressed in nasopharyngeal 
carcinoma cells and transcriptionally activates CHK1 
and CHK2 in CSCs [56]. Consistent with this, c-MYC 
was highly expressed during the early stage of sphere 
formation by SAS cells, prior to the increases in CHK1 
and CHK2 levels (Figure 4D, eighth panel from top, 
lanes 2–4). Expression of Scribble was maintained at 
comparatively high levels during the early stage and 
decreased slightly after the pre-SR stage (from 24 h 
onward), but did not dramatically oscillate between stages 
of sphere formation like LATS and TAZ (Figures 4D, 
seventh panel; 2A, fourth panel).
Taken together, these results suggest that 
phosphorylation and activation of LATS1/2 and SNAIL 
are required for initiation of self-renewal (i.e., the 
acquisition of self-renewal capacity) during sphere 
formation by CSCs, whereas dephosphorylation and 
inactivation of these proteins might be required for the 
maintenance of sphere formation during later stages. 
Notably in this regard, the expression levels and activities 
of LATS1/2, SNAIL, and TAZ are collaboratively up- or 
downregulated at the appropriate stages (timing) during 
sphere formation, which may be essential for self-renewal 
of CSCs.
SNAIL, CHK1, and Aurora-A are required for 
sphere formation in CSCs of OSCC
To further validate the importance of the 
LATS2–SNAIL axis in self-renewal, we fluorescently 
immunostained mature spheres of SAS cells with anti–
SNAIL-pT203 (a LATS2 phosphorylation site) and 
anti-SNAIL antibodies (Figure 5A). Cells positive and 
negative for SNAIL-pT203 expression were mixed in 
mature spheres, and expression of SNAIL protein was 
not necessarily correlated with cellular location within 
the sphere (e.g., inner vs. outer cells). Moreover, nuclear 
localization of SNAIL-pT203 was also observed in 
the staining-positive cells (Figure 5A, white arrows), 
consistent with a previous observation that LATS2-
mediated phosphorylation of T203 promotes nuclear 
accumulation and stabilization of SNAIL protein during 
EMT progression [25]. These results suggest that a 
mature sphere consists of heterogeneous cell populations 
that exhibit diverse molecular signals at different stages 
of sphere formation: pT203-positive cells may reflect 
CSCs vigorously undergoing self-renewal, whereas 
negative cells may reflect CSCs in which self-renewal 
was somewhat limited during sphere formation (Figure 
5A, white arrows and dashed open circles).
To confirm that SNAIL is essential for sphere 
formation in CSCs of OSCC, we transfected SAS cells 
with siRNA against SNAIL (siSNAIL/SAS), cultured 
the transfectants for 48 h, and then performed sphere 
formation assays in the absence of serum. Knockdown of 
SNAIL successfully inhibited sphere formation by SAS 
cells, even though SNAIL was not completely depleted 
(as determined by western blotting), suggesting that a 
threshold level of SNAIL is critical for sphere formation 
(Figure 5B–5D). Because T203 phosphorylation 
by LATS2 stabilizes SNAIL protein in the nucleus, 
these results also suggest that the LATS2–SNAIL 
axis promotes self-renewal. Similarly, knockdown of 
CHK1, MST2, or Aurora-A also successfully inhibited 
sphere formation (Figure 5E–5H), indicating that, like 
SNAIL and LATS1/2, these proteins are essential for 
self-renewal of CSCs of OSCC. Because the upstream 
factors of LATS, including MST2, CHK1, and Aurora-A, 
are required for sphere formation, the MST2/CHK1/
Aurora-A–LATS1/2 axis might contribute to self-renewal 
of CSCs in OSCC through phosphorylation of SNAIL 
and/or TAZ (Figure 6).
DISCUSSION
In this study, we demonstrated that LATS1/2 
are essential for self-renewal of OSCC cells with CSC 
properties, probably via activation of SNAIL and TAZ. 
Because we previously reported that LATS1/2 are pivotal 
in ensuring that cell division generates two daughter 
cells harboring equal genetic material [29, 57, 58, 59], 
the putative self-renewal initiation proteins, including 
LATS1/2, CHK1/2, and Aurora-A, are expressed at the 
highest levels during the process of sphere formation, 
and are likely activated to appropriately initiate and 
promote the successful completion of symmetric (i.e., self-
renewing) cell division (Figure 6).
In mammalian germ line stem cells, Aurora-A 
promotes symmetric division by regulating spindle 
orientation via PLK1 and the scaffold protein Gravin/
AKAP12 on the mother centrosome [60], and maintains 
Oncotarget1023www.oncotarget.com
self-renewal and pluripotency in embryonic stem cells 
by inhibiting p53-directed expression of  differentiation-
associated genes [61]. Notably, overexpression of 
Aurora-A promotes self-renewal of breast CSCs by 
stabilizing Wnt3a mRNA via suppression of miR-128, 
which collaborates with SNAIL [62]. Consistent with 
this, SNAIL positively regulates expansion and activity 
of breast CSCs via binding and subsequent degradation 
Figure 5: Deficiency of LATS2 axis–related proteins prevents sphere formation by SAS cells. (A) Immunofluorescence 
staining of SAS sphere with anti-SNAIL and anti–SNAIL-pT203 antibodies. Nuclei were counterstained with Hoechst 33258. White 
arrows indicate cells positive for SNAIL-pT203 expression. Dashed circles show cells negative for SNAIL-pT203 expression (red) but 
positive for SNAIL expression (green). Scale bars, 50 μm. (B) Western blot analysis of SNAIL in sphere lysates from control (siGL2) 
and SNAIL-knockdown (siSNAIL) SAS cells. α-tubulin was used as a loading control. (C) Representative phase contrast images of 
SNAIL-depleted (siSNAIL/SAS) and control SAS (siGL2/SAS) cells, grown under sphere formation conditions, on days 1 and 3. White 
arrows indicate spheres. Scale bars represent 100 μm. (D) Frequency of sphere formation in siSNAIL/SAS (green bars) and siGL2/SAS 
(blue bars) cells, grown under sphere formation conditions, on days 1 and 3. More than 120 cells were counted on day 1, and more than 
140 cells were counted on day 3. (E) Western blot analysis of CHK1 in lysates from control (siGL2) and CHK1-knockdown (siCHK1) 
SAS cells grown under adherent culture conditions. α-tubulin was used as a loading control. (F) Frequency of sphere formation in 
siCHK1/SAS (yellow bars) and siGL2/SAS (blue bars) cells, grown under sphere formation conditions, on days 1 and 3. More than 120 
cells were counted. (G) Western blot analysis of MST2 and Aurora-A in lysates from control (siGL2), MST2-knockdown (siMST2), 
and Aurora-A–knockdown (siAurora-A) SAS cells grown under adherent culture conditions. α-tubulin was used as a loading control. 
(H) Frequency of sphere formation in siMST2/SAS (pink bars), siAurora-A/SAS (light green bars), and siGL2/SAS (blue bars) cells, 
grown under sphere formation conditions, on days 1 and 3. More than 150 cells were counted on day 1, and more than 50 cells were 
counted on day 3.
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of p53 [63], and controls the switch between self-
renewal and differentiation in skeletal stem cells via an 
interaction with YAP/TAZ [64]. Moreover, in colorectal 
CSCs, SNAIL can also promote symmetric self-renewing 
division by inhibiting Numb expression via miR-146a 
[65]. These results suggest that SNAIL is a key factor 
not only in regulating the EMT, but also in promoting 
self-renewing symmetric division of CSCs. Importantly, 
LATS2 phosphorylates and stabilizes SNAIL during the 
EMT [25], which might contribute to initiation of self-
renewal and symmetric division of CSCs (Figures 2, 4 
and 5).
In mouse embryonic stem cells, LATS2 sustains 
stemness with pluripotency by inhibiting epigenetic 
repression of Oct4 and Nanog, probably by interacting 
with PRC2 to promote histone H3-K27 trimethylation, 
and can also execute the differentiation program in a p53-
dependent manner [66, 67]. Although LATS2 stabilizes 
p53 in human cancer cells by inhibiting MDM2 [68], it 
also might maintain stemness of SAS cells by inhibition 
of p53-dependent differentiation; SAS cells harbor a 
mutant p53 protein in which both the tetramerization 
domain and the C-terminal regulatory domain are deleted 
due to a truncation at E366 (http://p53.free.fr/Database/
Cancer_cell_lines/p53_cell_lines.html). However, 
because these deleted regions of p53 are dispensable 
for the interaction between p53 and SNAIL [63], the 
LATS2–SNAIL axis could ensure full execution of self-
renewal in SAS cells via SNAIL-mediated suppression of 
p53. By contrast, in non-CSC OSCC cell lines, although 
HSC3 cells lack any detectable p53 and HSC4 cells 
highly express a mutant p53 (R248Q) [69], LATS1/2 
Figure 6: Model of the role of LATS1/2 kinases in the pre–self-renewal (pre-SR) stage during sphere formation by 
CSCs. The process of sphere formation of CSCs consists of four stages: early, pre-SR, initiation of self-renewal (in-SR), and mature sphere 
formation. LATS1/2 are required for self-renewal via regulation of TAZ and SNAIL. The solid and dashed lines show imaginary lines, not 
actual values, of independent expression and/or activity levels of the indicated proteins. Black arrows show the direction of the signaling 
cascade found in this study.
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were expressed at relatively low levels in these cell lines 
(Figure 1).
At the early stage of sphere formation before the 
pre-SR stage, expression and activity of LATS2 were 
transiently decreased in a Scribble-independent manner, 
which may be important for the early stage–specific 
accumulation of TAZ (Figure 4). Because OCT4 and 
NANOG repress the expression of LATS2 by binding to 
a near region of the LATS2 gene [30, 70], these proteins 
(which are highly expressed in SAS cells [43]) might be 
responsible for transient suppression of LATS2 during 
the early stage. TAZ confers self-renewal capacity on 
non-CSC breast cancer cells, acting downstream of 
the induction of EMT and subsequent inactivation of 
Scribble [21]. Furthermore, expression of LATS1/2 is 
downregulated by promoter methylation in developing 
OSCC tissues [71], which are probably heterogeneous 
cell populations containing mostly non-CSCs. Therefore, 
the transient suppression of LATS2 during the early stage 
may be essential for acquisition of CSC properties during 
the earlier phase prior to initiation of self-renewing cell 
division. However, we found that, in SAS cells, TAZ 
was activated before the EMT (SNAIL activation and 
N-cadherin induction) in a Scribble-independent manner, 
suggesting that the molecular mechanisms by which non-
CSCs acquire self-renewal capacity differ slightly between 
OSCC and breast cancer.
Collectively, our results provide a new insight into 
the molecular mechanisms by which CSCs execute self-
renewal and non-CSCs acquire the property of stemness. 
This knowledge should facilitate the development of 
advanced medical treatments targeting CSCs expressing 
LATS kinases.
MATERIALS AND METHODS
Cell culture
Three OSCC cell lines, HSC3, HSC4, and SAS, 
were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (FBS, Hyclone, 
Logan, UT, USA), 100 U/mL penicillin, and 100 μg/mL 
streptomycin, and incubated at 37°C and 5% CO2. These 
cell lines were provided by the RIKEN Bio Resource 
Center, Ibaraki, Japan [44]. SCC-4 cells were obtained 
from the JCRB Cell Bank (#JCRB9118; Osaka, Japan) and 
were cultured in DMEM/F12K (1:1) supplemented with 
10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 
and 0.4 μg/mL hydrocortisone (Sigma-Aldrich).
Sphere formation assay
Cells were trypsinized and mechanically 
dissociated by repeating shearing through a 25G 
injection needle to avoid a cell aggregation (i.e., 
doublets and triplets). Single cells were plated in EZ-
Bind Shut II (IWAKI, Chiba, Japan) at 400 cells/cm2 
and grown in sphere culture medium [DMEM/F-12K 
(1:1), supplemented with B27 (Invitrogen, San Diego, 
CA, USA), 20 ng/mL EGF (Sigma-Aldrich), 20 ng/mL 
bFGF (Sigma-Aldrich), 2 mM glutamine (Invitrogen), 
and penicillin/streptomycin]. After incubation at 37°C 
and 5% CO2 for the indicated times, the spheres were 
analyzed by microscopy. To examine earlier stages of 
self-renewal, spheres with diameters of larger than 20 
mm were counted.
Subcellular fractionation
Cells were separated into cytoplasm, cell membrane, 
nucleus, and cytoskeleton fractions using the ProteoExtract 
Subcellular Proteome Extraction Kit (S-PEK; Calbiochem, 
La Jolla, CA, USA). Prior to electrophoresis, the proteins 
were denatured by boiling for 7 min in Laemmli sample 
buffer.
Treatment with MG132
SAS cells (2 × 105 cells/dish) were plated in 60 mm 
dishes. Five days after seeding, the cells were exposed 
to 20 μM MG132 (Calbiochem) in DMEM/10% FBS 
medium and incubated for 2 h at 37°C under 5% CO2. 
After washing in PBS (-), the cells were fractionated by 
S-PEK.
Western blot analysis
To prepare the total cell extracts, the cells were 
lysed by RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium 
deoxycholate) supplemented with 100 μg/mL PMSF, 1 μg/
mL aprotinin, 10 μg/mL leupeptin, 1 μg/mL pepstatin A, 
1 mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate. 
The denatured proteins were separated by SDS-PAGE 
and transferred onto PVDF membranes (Immobilon P; 
Millipore, Billerica, MA, USA). After blocking with 5% 
skim milk or 5% BSA in TBST (20 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 0.05% Tween 20), the membranes 
were probed with the indicated primary antibodies, 
followed by washing in TBST and incubation with HRP-
conjugated secondary antibodies. Protein bands were 
visualized using the Western Lightning Plus ECL reagent 
(Perkin Elmer, Waltham, MA, USA). The intensities of 
bands were quantified using ImageJ software.Full scan 
images of blots were shown in Supplementary Figure 3.
Antibodies
Commercial antibodies were obtained from 
the indicated suppliers: Lamin A/C (4C11), LATS1 
(C66B5), LATS1-pT1079 (D53D3), SNAIL (L70G2) 
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monoclonal and E-cadherin, MAPK, MST2, N-cadherin, 
p-MST1/2 (pT183/pT180), and YAP-pS127 polyclonal 
antibodies from Cell Signaling Technology (Danvers, 
MA, USA); vimentin (VIM 3B4) monoclonal antibody 
from American Research Products (Waltham, MA, 
USA); YAP (H-9) monoclonal and 14-3-3γ and Scribble 
polyclonal antibodies from Santa Cruz Biotechnology 
(Dallas, TX, USA); 14-3-3γ (pS58) polyclonal antibody 
from Abcam (Cambridge, UK); actin (AC-40), α-tubulin 
(B-5-1-2), CHK1 (DCS-310), and CHK2 (DCS-270) 
monoclonal and TAZ (WWTR1) polyclonal antibodies 
from Sigma-Aldrich; LATS2 polyclonal antibody from 
Bethyl Laboratories (Montgomery, TX, USA); Myc 
(9E10) and Myc (PL14) monoclonal antibodies from 
Upstate (Bedford, MA, USA) and MBL (Nagoya, Japan), 
respectively; and GAPDH monoclonal antibody from 
Fitzgerald (Acton, MA, USA). Aurora-A, LATS2-pS408, 
LATS2-pS835, LATS2-pT1041, SNAIL-pT203, and YAP 
(GS) polyclonal antibodies were described previously [25, 
46, 54, 55, 58].
Plasmids, siRNAs, and transfection
Human YAP2 ORF was isolated by PCR-based 
cloning from a human myometrium cDNA library. The 
full-length human YAP2 cDNA was inserted into the 
AscI and NotI sites of mammalian expression vector 
pCMV6myc (+AscI), a modified version of pcDNA3. 
Plasmid DNAs were transfected into SAS cells using 
Lipofectamine and PLUS reagents (Invitrogen). At 48 h 
after transfection, the cells were trypsinized and subjected 
to the sphere formation assay. For western blot analysis, 
lysates were prepared from cells cultured for 1 day under 
sphere formation conditions (SAS-s).
Sequences of siRNA duplexes 
were as follows: siLATS1 (#3509), 
5’-ACUUUGCCGAGGACCCGAAdTdT-3’; 
siLATS2 (#31), 5’-CCGCAAAGGGUAC
ACUCAACUCUGUdTdT-3’; siTAZ (#2), 
5’-AGAGGUACUUCCUCAAUCAdTdT-3’; siCHK1 
(#477), 5’-UCGUGAGCGUUUGUUGAACdTdT-3’; 
and siGL2 (firefly luciferase), 
5’-CGUACGCGGAAUACUUCGAdTdT-3’. siSNAIL 
(Human SNAI1, ##SR304489C) and siMST2 (Human 
STK3, #SR304635B) were purchased from OriGene 
Technologies (Rockville, MD, USA). siRNA duplexes 
were introduced into HSC3, SAS, or SCC-4 cells using 
Oligofectamine or Lipofectamine 2000 (Invitrogen). At 
48 h after transfection, the cells were trypsinized and 
subjected to the sphere formation assay. For western blot 
analysis, lysates were prepared from the cells cultured 
for 1 day (Figures 2A, 2C, 5B and Supplementary 
Figure 2A) or 3 days (Supplementary Figure 1D) 
under sphere formation conditions (HSC3-s or SAS-s) 
or conventional adherent culture conditions (HSC3-a, 
SAS-a, or SCC-4-a).
Immunofluorescence
Spheres were plated on cover glasses in 6-well 
plates and fixed with 3.5% paraformaldehyde in PBS 
(-) for 10 min at room temperature. The sphere cells 
were then permeabilized with 0.2% Triton X-100 in 
PBS (-) for 5 min at room temperature. For indirect 
immunofluorescence (IF), the cells were blocked 
with 2% BSA in PBS (-) for 1 h, incubated overnight 
at 4°C with anti-SNAIL-pT203 polyclonal and anti-
SNAIL monoclonal antibodies, and then incubated with 
secondary antibody (Alexa Fluor 488 goat anti-rabbit 
IgG or Alexa Fluor 594 goat anti-mouse IgG; Molecular 
Probes, Eugene, OR, USA) for 1 h at room temperature. 
After the samples were washed with PBS (-), DNA 
was counterstained with Hoechst 33258 (SIGMA). The 
samples were treated with SlowFade reagent (Thermo 
Fisher Scientific, Waltham, MA, USA) and observed on a 
FV10i FLUOVIEW confocal laser scanning microscope 
(Olympus, Tokyo, Japan).
Statistical analysis
Statistical analysis was performed in Microsoft 
Excel. All data on sphere formation assays are shown 
as means and standard deviations of three independent 
experiments, except for those in Figure 3E, 3F and 
Supplementary Figure 2B (n = 1). P-values were 
calculated using Student’s t-test. *p < 0.05, **p < 0.01, and 
***p < 0.001. N.S., no significant difference.
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